News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GammaCan International, Inc. (GCAN.OB) Release: VitiGam(TM) Inhibits Melanoma Growth in a Dose Dependent Manner


8/11/2008 8:19:16 AM

KIRYAT ONO, Israel & NEW YORK--(BUSINESS WIRE)--GammaCan International, Inc. (“GammaCan” or “the Company”) (OTCBB: GCAN), a developer of proprietary immunotherapies for the treatment of melanoma and other cancers, today announced further progress in its VitiGam™ development program. In preparation for its upcoming IND submission for VitiGam™, the Company successfully completed additional experiments using its established mouse melanoma model. These studies demonstrate a dose response of tumors (human melanoma cells) when treated with IgG preparations derived from vitiligo donors. In addition, the Company has conducted a meta-analysis (a statistical analysis of a large number of experiments) based on a series of previously announced studies with its mouse melanoma model. The results of this meta-analysis further confirm the effectiveness against melanomas of IgG preparations derived from vitiligo donors.

Read at BioSpace.com

comments powered by Disqus
   
Melanoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES